UCB PharmaSlough, United Kingdom
2430: Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Monday, November 18, 202410:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose